Last reviewed · How we verify
Non-valvular atrial fibrillation
Approved treatments
- Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process. - Dabigatran Etexilate · Boehringer Ingelheim
Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Non-valvular atrial fibrillation patent landscape — cliff calendar, originator estates, attackable patents
- Non-valvular atrial fibrillation treatment landscape brief
- Non-valvular atrial fibrillation treatment updates RSS
Frequently asked questions about Non-valvular atrial fibrillation
What drugs treat Non-valvular atrial fibrillation?
Tracked treatments include Dabigatran Etexilate.
What is the treatment for Non-valvular atrial fibrillation?
Standard treatment for Non-valvular atrial fibrillation includes Dabigatran Etexilate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Non-valvular atrial fibrillation patent cliff · Non-valvular atrial fibrillation CI report
- Treatment: Dabigatran Etexilate · Boehringer Ingelheim
- Treatment: Dabigatran Etexilate · Boehringer Ingelheim
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing